Company Raises $3.85M in Seed Funding led by Caduceus Capital Partners, with Participation
from Bread and Butter Ventures; Announces Collaboration with Mayo Clinic

SAN FRANCISCO, Feb. 14, 2025 — VoiceCare AI, a healthcare administration general intelligence (HAGI) company, announced plans to automate back-office conversations and super-staff the workforce through the application of generative AI. The company’s agentic architecture platform is built to optimize and ease administrative burden and radically improve operational efficiency. With $3.85 million in funding led by Caduceus Capital Partners, and participation from Bread and Butter Ventures, VoiceCare AI seeks to improve access, adherence, and outcomes for patients and the healthcare workforce, putting the focus back on patient engagement.

Every year, countless calls with long hold times occur in the healthcare system, transferring and copying data, verifying statuses and follow-ups, or starting a process. According to McKinsey & Company, healthcare administration in the United States currently accounts for $1 trillion of the $4.5 trillion total healthcare spend, and more than 90% of healthcare-related calls are still being handled manually between humans. VoiceCare AI is looking to tackle this challenge head-on with “Joy,” its human-like voice AI agent built to support long, complex, and highly nuanced conversations and extended hold times.

“Imagine a world where the time spent on manual phone calls and faxes is replaced by meaningful patient interactions. With generative AI, we want to make this a reality,” said Parag Jhavari, founder and CEO of VoiceCare AI. “By automating conversations in a way that feels genuinely human, we seek to give back time to healthcare professionals so they can focus on high-order patient care, driving radical efficiencies with every conversation. That’s why we created “Joy,” our voice AI agent. We want to give healthcare professionals more time to focus on what truly matters—caring for patients.”

VoiceCare AI also announced a pilot with Mayo Clinic to employ its intelligent voice automation for use cases including patient pre-authorization and benefit confirmations within three separate areas – the Department of Neurology, Department of Pediatrics, and Medical and Administrative Support Operations.

The funding will support team expansion, enhanced sales and marketing efforts, and continued investment in enhancing platform accuracy, security and compliance.

“At Caduceus Capital Partners, we’re passionate about funding technologies that improve efficiency and reduce administrative costs. VoiceCare AI has the potential to provide a much-needed solution to providers, and we’re proud to support this team as they grow the business,” said Dave Vreeland, senior managing partner at Caduceus Capital Partners.

“VoiceCare’s technology has potential to empower clinical and healthcare staffing teams to focus on patient care and alleviate administrative burdens,” said Mary Grove, Managing Partner at Bread and Butter Ventures. “They are attempting to solve pain points we’ve all experienced as patients and driving value for patients, providers, and payers. We’re thrilled to back Parag’s big vision to tech-enable the administrative layer of healthcare.”

How it Works

Every year healthcare administrators and providers spend 60-80% of their time on insurance- and billing-related tasks instead of patient care. VoiceCare AI transforms B2B voice conversations through intelligent automation. Its AI platform handles payer communication, from benefits verification to prior authorizations and claims follow-ups. By automating time-consuming calls, the company seeks to free staff from hours of hold times while maintaining detailed documentation and a call summary of every interaction. The system is designed to integrate seamlessly with existing workflows and provides near real-time status updates.

The company’s technology leverages advanced multi-modal, multimodal agentic architecture with reinforcement learning from human feedback (RLHF) and proprietary healthcare conversational data to achieve a near-perfect call completion accuracy rate, with a majority of calls completed autonomously using AI. VoiceCare’s development team takes a safety-focused approach as the platform is HIPAA compliant and SOC 2 Type II attested.

The VoiceCare advisory board has deep healthcare, technical and AI experience. They include: Andrew Vaz, Mary Grove, Paul Conley, Mark Nathan, James Fan, and Dr. Sheena Menezes.

Mayo Clinic has a financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About VoiceCare AI

VoiceCare AI is a healthcare administration general intelligence (HAGI) company built to automate back-office conversations and super-staff the workforce through the application of generative AI. The company’s AI voice-based automation and agentic AI architecture massively eliminates administrative burden and improves operational efficiency. “Joy,” its human-like voice AI agent, is capable of supporting long, complex, and highly nuanced conversations and extended hold times. VoiceCare AI has raised $3.85 million in seed funding led by Caduceus Capital Partners, and participation from Bread and Butter Ventures. For more information, visit us at Voicecare AI and follow us on LinkedIn and YouTube.

Media Contact
Audrey Mann Cronin
[email protected] 

SOURCE VoiceCare AI

Company Opens Fundraising Round to Scale AI-Driven Diagnostics & Treatment Simulations

DENVER, Feb. 14, 2025 — NeuralCure AI, an emerging leader in AI-powered healthcare technology, today unveiled its groundbreaking platform capable of compressing a century of medical research into a single day. By leveraging AI-driven diagnostics and rapid treatment protocol simulations, NeuralCure AI is pioneering perfect-match treatment solutions that seamlessly integrate into research and patient care, accelerating breakthroughs at an unprecedented pace.

To scale its technology and expand its global healthcare impact, the company has officially opened its fundraising round, inviting investors to participate in shaping the future of precision healthcare.

Revolutionizing Healthcare with AI-Powered Simulations

NeuralCure AI’s proprietary technology runs over 10,000 treatment simulations daily on digital twins, rapidly identifying and refining the most effective patient-specific treatment strategies for conditions such as cancer, neurodegenerative diseases, and metabolic disorders.

“For decades, medical research has been trapped in slow, incremental cycles,” said Orin Wilson, spokesperson for NeuralCure AI. “We’ve shattered that bottleneck. Our AI-driven simulations can process the equivalent of 100 years of medical discoveries in a single day, unlocking perfect-match treatment protocols that seamlessly integrate into research studies and patient care.”

How NeuralCure AI is Transforming Healthcare

NeuralCure AI’s platform delivers AI-driven solutions for both diagnostics and treatment planning by:

• Aggregating and integrating diverse data sources, including imaging scans, genomic profiles, real-world environmental data, and neurological patterns, providing insights that other AI models overlook.
• Instantly analyzing medical images and videos to detect diseases and abnormalities with unmatched precision.
• Running thousands of rapid treatment protocol simulations per day to refine patient-specific interventions.
• Developing AI-powered “perfect match” treatment protocols that integrate with research studies or real-world treatment plans.
• Using neuro-programming interfaces to activate the body’s natural healing processes.

“We’re not just predicting disease, we’re engineering the fastest, most effective way to treat it,” Wilson added. “By unlocking AI-driven precision medicine, we’re making healthcare faster, smarter, and more accessible than ever before.”

Fundraising Round Now Open to Accelerate Growth

To further develop and deploy its AI-powered medical solutions, NeuralCure AI has launched a new fundraising round. This investment will enable the company to:

• Expand AI-driven research partnerships with leading hospitals, universities, and medical institutions
• Scale digital twin treatment simulations to refine life-saving therapies
• Deploy AI diagnostics and treatment protocols into real-world applications with current customers

“This is the future of healthcare,” said Ryan Doelling, early investor from thebad.company . “NeuralCure AI isn’t just improving medical diagnostics, it’s transforming how we approach disease prevention, treatment, and recovery. Their ability to simulate thousands of treatments per day and develop precision-tailored protocols is a game-changer for the industry.”

Partner with NeuralCure AI

NeuralCure AI is actively seeking partnerships with research organizations, healthcare providers, medical imaging companies, and treatment facilities to integrate its AI-powered solutions.

To explore investment or partnership opportunities contact [email protected].

About NeuralCure AI

NeuralCure AI is a cutting-edge AI healthcare technology company redefining medical research and patient care through AI-driven diagnostics, medical imaging analysis, and neuro-programming solutions. By accelerating discovery cycles and perfecting treatment protocols, NeuralCure AI is making the impossible possible, compressing decades of medical advancement into days.

Media Contact:
[email protected] 
NeuralCure AI

NeuralCure AI: Advancing Healthcare at the Speed of AI.

SOURCE NeuralCure AI, Inc.

ASHEVILLE, N.C., Feb. 13, 2025 — Surus, an institutional-grade asset management and custody platform for onchain finance, announced today that it received regulatory approval from the North Carolina Commissioner of Banks to open Surus Trust Company, a wholly owned subsidiary.

Surus’s mission is to accelerate and improve the onchain financial ecosystem. Powered by Surus Trust Company, the Surus platform equips builders with the tools to create, sell, and manage tokenized assets within a time-tested and regulated legal structure. The platform’s offerings include fiduciary asset management services, custody for traditional and crypto native assets, brokerage and payment system connectivity, compliance tools, and multichain tokenization capabilities.

“As finance moves onchain, the market needs digitally native infrastructure that is flexible enough to support tokenized assets of all kinds within compliant, bankruptcy-remote legal structures,” said Patrick Murck, founder and CEO of Surus, “We’re eager to partner with the builders making the onchain future of finance a reality.”

“North Carolina has been a terrific partner in creating this de novo digitally-native financial institution and we look forward to continuing our work with the North Carolina Commissioner of Banks and staff.”

In Q1 2025, Surus is partnering with companies to service three lines of business:

• Reserve Management for Tokenized Assets and Stablecoins: Supporting creators of tokenized financial products and stablecoins with customizable asset reserve management and settlement services.
• Digital Asset Trusts: Enabling offchain investors to securely and transparently access onchain investment opportunities, such as owning curated digital asset portfolios or participating in DeFi ecosystems.
• End-to-End Tokenization and Custom Fiduciary Services: Working with startups and traditional firms alike to go from 0 to 1 with tokenized financial products powered by Surus’s platform.

Surus completed an $8 million series seed bringing their total amount of funding raised to over $10 million. The latest financing was led by Castle Island Ventures with participation from Propel Ventures, Restive Ventures, Protagonist, Protocol VC, and Plural VC.

“The tokenization of dollars and other assets is the unambiguous killer app of blockchains so far,” said Nic Carter, GP of Castle Island Ventures. “There is a distinct lack of credible regulated intermediaries in the sector, and Surus is poised to change that. I am thrilled to be backing Surus and joining the board.”

For more information about Surus and its services, visit surus.io

Contact:

[email protected] 

SOURCE Surus

Brevan Howard Digital, Karatage, Token Bay, Pharsalus and others join in supporting Soter’s mission to provide specialized insurance products for the digital asset sector

ABU DHABI, UAE, Feb. 13, 2025 — Soter Insure, a provider of specialized insurance products tailored to the digital asset economy, has successfully closed its Series A funding round, led by Galaxy, with participation from Brevan Howard Digital, Karatage, Token Bay, Pharsalus and others.

Headquartered in Abu Dhabi and operating out of Bermuda, with offices in London, New York and Dubai, Soter Insure was incubated by Further Ventures and WebN Group. The company offers specialized digital asset insurance products for financial institutions, including Asset Loss, Directors & Officers (D&O), and Smart Contract Failure coverage, uniquely denominated in both fiat and native digital assets.

As the Web3 space continues to evolve, the lack of adequate insurance products and scarce capacity has been a significant barrier to broader adoption. Soter Insure addresses this gap by offering comprehensive insurance solutions tailored to the unique risks of decentralized technologies, thereby instilling confidence in institutional and retail participants.

The investment will support Soter Insure’s expansion, bolstering its underwriting and technology teams to scale operations across key markets.

“Our mission at Soter is to set a new standard for risk management in the digital assets space. We are proud to have the support of Galaxy and our other Series A investors as we work to build innovative insurance products that meet the unique needs of the market. With this funding, we’ll continue to expand our offerings and grow our footprint globally, providing clients with trusted and transparent risk management solutions,” said Henson Orser, Founder and CEO of Soter Insure.

Mike Novogratz, Founder and CEO of Galaxy, added, “Galaxy is excited to support Soter Insure in their mission to bring innovative insurance solutions to the digital asset ecosystem. Their tailored approach to risk management meets a crucial industry need, empowering digital asset holders and operators with confidence. We are excited to contribute to their growth and global expansion.”

For more information about Soter Insure, visit soter.insure.

About Soter Insure
Soter Insure is a leading provider of specialized insurance solutions for the digital asset economy. With a focus on institutional investors, Soter offers a range of innovative insurance products that address the unique risks of the blockchain ecosystem. Soter Insure is committed to providing robust, transparent, and secure risk management solutions. For more information, visit www.soter.insure

SOURCE Soter Services North America LLC

SAN FRANCISCO, Feb. 13, 2025 — Tofu, the unified AI platform for B2B marketing teams, today announced it has raised $12 million in Series A funding. The investment was led by SignalFire, with participation from HubSpot Ventures, Tau Ventures, Correlation Ventures, Alumni Ventures, SH Fund, Riverside Ventures, Eudemian Ventures, and Han Bridge Capital, alongside a notable group of angel investors. Existing investors Index Ventures, Stage 2 Capital, and Liquid 2 Ventures also participated in the round.

Tofu’s unified platform addresses a critical pain point for marketing teams: the overwhelming proliferation of martech tools. By consolidating campaign execution under one roof, Tofu enables GTM teams to create personalized, omni-channel campaigns at scale without the burden of managing multiple point solutions.

Over the past year, Tofu has experienced tremendous growth, with a 12x increase in revenue and a 36x surge in content generated on the platform. Tofu has gained traction with marketing teams of various sizes, from fast-growing startups to enterprise organizations like RingCentral, Check Point and Bluecore.

“This capital accelerates our mission to build a unified AI platform for GTM teams. We’re grateful for our investors’ support and customer feedback, which drive us to create a comprehensive, one-stop solution that helps marketing teams scale campaigns across a wide range of use cases,” said EJ Cho, Ço-founder and CEO of Tofu.

Companies leveraging Tofu have experienced significant improvements in their marketing performance and revenue growth. The approach to consolidate omni-channel campaigns under one umbrella has enabled teams to execute campaigns more efficiently, resulting in a tremendous increase in engagement and conversion across multiple channels. Teams using the platform have seen up to 75% reduction in campaign creation time, and a 230% increase in engagement rates across their marketing channels. Tofu’s platform caters to diverse GTM teams and their specific needs whether it’s demand generation, content marketing, lifecycle marketing, event marketing, digital marketing, or outbound SDR campaigns.

“Tofu is the end of one-size-fits-none marketing, and the true beginning of generative marketing, through omni-channel hyper-personalized campaigns that scale. Customers have raved about the 10x+ lift in content output for time strapped marketing teams and 20 percent downstream conversion lift. There’s no better team to capitalize on the opportunity, as EJ, Elaine and Honglei represent the perfect combination of AI/ML expertise and customer empathy as GTM practitioners” – Wayne Hu, Partner @ Signal.

For more information about Tofu and its unified AI platform for GTM teams, visit tofuhq.com.

About Tofu:

Tofu is an omnichannel marketing platform that helps B2B marketing teams scale their campaigns by personalizing content for different customer segments and repurposing content across channels. With its flexible workflows, marketing teams can efficiently create and execute campaigns for demand generation, content marketing, lifecycle marketing, event marketing and more. Tofu enables marketing teams to build cohesive, on-brand campaigns at scale while reducing martech bloat and improving efficiency.

SOURCE Tofu

TORRANCE, Calif., Feb. 13, 2025 — K2 Space today announced its $110 million Series B to ramp up mass production of its multi-orbit, high power satellite platform. The funding round, co-led by Lightspeed Venture Partners and Altimeter Capital, includes participation from existing investors Alpine Space Ventures, First Round Capital, and others. This milestone comes as K2 celebrates the opening of its new 180,000 square foot factory in Torrance, California, and the success of its first in-space demonstration flying a number of critical components developed in-house. Since its inception, K2 Space has raised $180M in equity and won over $50M in government and commercial contracts.

K2 Space is changing the economics of satellite connectivity and functionality, having designed a resilient, high power, high payload mass satellite platform at a cost that enables proliferation across orbits. With increasing demand for proliferated space applications requiring high throughput and levels of compute, K2’s solution provides an answer for customers who, until now, have been forced to trade between performance and affordability. The company plans to use the newly raised capital to scale production, hire talent, and bring additional components in-house.

“Advanced space capabilities can’t be built on small, low-powered platforms,” said Karan Kunjur, CEO at K2 Space, “but higher capability satellites have been far too expensive for most proliferated applications. This is the gap K2 fills – making highly capable, powerful satellites available to a much broader market. And because our satellites are designed to proliferate in higher orbits, our constellations require fewer satellites and fewer launches to provide global coverage.”

K2 Space recently announced a government contract for its first mission, “Gravitas”, which is designed to both demonstrate the platform’s ability to operate in the high radiation environment of medium-earth orbit (MEO), and perform the first of its kind low earth orbit (LEO) to MEO electric propulsion orbit raise. Taking advantage of the platform’s high power generation and versatile payload deck, the Gravitas mission will carry a mix of National Security and commercial payloads, demonstrating the ability to execute against critical mission areas while enabling a wide variety of space applications.

“We are at the dawn of a Space Supercycle,” said Erik Kriessmann, Partner at Altimeter Capital, “where new launch vehicles and reduced-cost, reliable access to space are transforming the entire market. K2 Space is taking advantage of this paradigm shift by mass-manufacturing multi-mission satellites that deliver unprecedented capabilities and enable multi-orbit constellations.” Added Connor Love, Partner at Lightspeed Venture Partners, “As the demands of space operations evolve, so too must the capabilities of satellite builders.”

K2 Space is entering 2025 on the heels of a blockbuster 2024 for the company. In addition to winning new government and commercial business, the company scaled from 25 to 90 full-time employees, and successfully completed full activation and operation of all hardware launched on its first in-space mission, including the flight computer, microcontroller core board, motor controller, and reaction wheel. Given how much of the bus K2 is building in-house, this successful component mission represents a major milestone – burning down significant technical risk – in preparation for Gravitas.

“We’ve attracted huge interest from both commercial and national security customers, who tell us that the platform we’ve designed is unique, differentiated, and unlocks a multitude of pressing applications for their organizations,” Karan continued. “As we’ve been able to prove out our technology and price point, customers have expressed greater excitement – but also urgency – in what we’re building. The Series B is a vote of confidence from our investors, and importantly, allows us to more quickly address what is a critical gap in the market.”

About K2 Space

K2 Space is developing a high-powered, low-cost satellite bus platform that delivers the capability of exquisite satellites at the price point and speed of small satellites. Redesigned from the reaction wheel up, the K2 bus multi-manifests up to ten satellites per launch vehicle, is made to handle the harsh environment of MEO and GEO, and has the highest power electric propulsion system ever flown – making it the platform of choice for Proliferated LEO, Proliferated MEO, and Proliferated GEO.  K2 Space was started by a team of former SpaceX engineers and has raised $180M in venture capital to date, with the backing of leading funds like Lightspeed Venture Partners, Altimeter Capital, and First Round Capital.

Media Contact: [email protected]

SOURCE K2 Space

SAN FRANCISCO, Feb. 13, 2025 — Vouch, the leading business insurance provider for high-growth companies, today announced that it has signed a definitive agreement to acquire the team and book of business of StartSure Insurance Services, Inc., an insurance provider that simplifies how small businesses get insurance.

Vouch is also announcing the first close of its Series D funding round, led by Allegis Capital with all other major investors participating, reinforcing its position as the go-to insurance platform for high-growth companies.

As part of the acquisition, the StartSure team, including CEO Tim DiPietro, will join Vouch. StartSure clients will gain access to a broader suite of insurance products through Vouch’s brokerage team, while Vouch clients will benefit from StartSure’s proprietary MGA programs for coworking and inventory insurance.

“Through this Series D financing and joining forces with StartSure, Vouch is expanding our capabilities to provide unmatched service and innovative products to high-growth companies,” said Sam Hodges, CEO of Vouch. “StartSure’s expertise in insuring startups and flexible workspaces aligns perfectly with our mission, and our latest funding will allow us to expand our brokerage capabilities and develop new insurance products.”

Tim DiPietro, CEO of StartSure, added: “Vouch is a natural home for StartSure. We share a commitment to making insurance simple and accessible for founders. Joining forces means our clients will benefit from expanded resources, broader coverage options through Corix, and Vouch’s reputation for exceptional service.”

With the backing of Allegis Capital and the integration of StartSure, Vouch is accelerating its expansion, ensuring that startups—no matter their stage—have access to tailored, high-quality insurance solutions.

About Vouch

Vouch is the tech-enabled insurance provider for high-growth companies, with access to 80+ insurance carriers and instant quoting capabilities through our MGA brand, Corix. Backed by industry experts and top-tier investors, Vouch provides fast, tailored, and founder-friendly insurance solutions to help startups manage risk at every stage. With a tech-driven approach and deep expertise in emerging risks, Vouch is redefining how entrepreneurs protect their futures. For more information, visit vouch.us.

About StartSure

StartSure is the insurance platform built for modern businesses. Designed to remove the complexity of coverage, StartSure offers fast, flexible, and transparent insurance solutions tailored for startups, small businesses, and entrepreneurs. Whether it’s general liability, cyber protection, or tenant coverage, StartSure delivers seamless, tech-driven policies that grow with your business. For more information, visit startsure.co

Media Contact
Clark Kays
[email protected]

SOURCE Vouch

SAN CARLOS, Calif. and DALLAS, Feb. 13, 2025 — Trive Capital (“Trive”), the Dallas-based private equity firm, is excited to announce its recent investment in Chilton Auto Body (“Chilton” or the “Company”). Headquartered in San Carlos, California, Chilton is a leading collision repair platform operating 20 auto body repair shops across California.

For over 55 years, Chilton has provided its customers with a comprehensive range of auto body collision repair services, from structural damage and bumper repair to light cosmetic and paintless dent repairs. While the Company services all vehicle makes and models, Chilton specializes in repairing electric vehicles (“EV”) from OEMs Tesla, Rivian and Lucid, among others. The Company was the first Tesla-certified body shop and is recognized as a pioneer of EV collision repair.

“Today’s announcement marks a pivotal moment for our company and is a testament to the commitment and strength of our team, our track record for quality and timely repairs, and our relentless focus on providing an industry-leading customer experience,” said Mike Chilton, Chief Executive Officer of Chilton Auto Body. “We are thrilled to partner with Trive as we launch this new phase of growth, while enhancing support for our valued insurance carrier partners and creating new opportunities for our talented team members.”

The Company was founded in 1969 when Charles Chilton opened its first repair shop in San Mateo, California. In 1984 Mike Chilton joined his father in running the business, and starting in 2003 under his leadership, the Company began expanding its shop footprint via brownfield and acquisition. Chilton now operates 20 state-of-the-art repair shops around the Bay Area and Los Angeles and continues to grow throughout California.

“The Chilton leadership team has an exceptional track record of growing its footprint and scale, performing to key scorecard metrics, and delivering quality customer service, all while maintaining industry leading capabilities and EV repair expertise,” stated Jared Reyes, Managing Director at Trive Capital. “We are excited to partner with Mike and the executive team as they look to bring Chilton’s exceptional service and capabilities to new and adjacent geographies via M&A and new brownfield locations.”

“The collision repair industry continues to demonstrate attractive fundamentals. Furthermore, the growing complexity of vehicles and further adoption of EVs together present an attractive market opportunity for players with leading capabilities, state-of-the-art equipment and highly experienced technicians,” added Chris Zugaro, Partner at Trive Capital. “Chilton’s history and reputation position them well to capitalize on these trends, and we look forward to partnering with them in this next chapter of growth.”

King & Spalding LLP served as legal counsel to Trive.

About Chilton Auto Body
Headquartered in San Carlos, California, Chilton Auto Body is a leading U.S. auto body collision repair platform operating 20 shop locations across California. Chilton offers its valued customers a range of collision repair services, including paint and refinish, aluminum welding, bumper repair and calibration, light cosmetic, structural damage repair, and paintless dent, in addition to select ancillary services such as hail damage repair. Chilton’s origins date back to 1969 when the Chilton family opened the Company’s first repair shop in San Mateo, California. For more information, visit www.chiltonautobody.com.

About Trive
Trive Capital is a Dallas, Texas-based private equity firm with more than $8 billion of regulatory assets under management. Trive focuses on investing equity and debt in what it sees as strategically viable middle-market companies with the potential for transformational upside through operational improvement. We seek to maximize returns through a hands-on partnership that calls for identifying and implementing value creation ideas.

The Trive team is comprised of seasoned investment professionals who have been involved in over 250 middle-market transactions representing in excess of $10 billion in revenue across Trive’s targeted industry sectors and situations.

SOURCE Trive Capital

This is the first tranche of a Series A Round for IBI Ag’s novel bioinsecticide platform.

NES TZIONA, Israel, Feb. 13, 2025 — IBI Ag, a pioneering crop protection company developing a wide array of bio-insecticides with a lower ecological footprint, today announced it has successfully closed the first part of its Series A funding round with a $6.1 million investment. This round—led by Corteva, Inc. (“Corteva”), through its Corteva Catalyst platform with the participation of The Trendlines Group (SGX:42T) (OTCQX:TRNLY), Iron Nation, Consensus Business Group (“CBG”) and a grant from the Israel Innovation Authority —underscores the strategic importance of IBI Ag’s innovative biological and naturally-inspired solutions in the global agricultural sector to assist farmers in producing more food by protecting their crops and the global food chain.

IBI Ag has developed technology that leverages single domain antibodies, to produce highly effective crop protection solutions with a low ecological footprint. This technology—adapted from pharma and modified to fit the agricultural market—provides novel modes of action and represents a revolutionary new approach for protecting crops from insects. The products under development target a broad spectrum of insects, both sucking and chewing insects with minimal impact on non-targeted organisms. The company is targeting high value crops to start and will follow with row crop solutions.

“We are thrilled to have the support of our existing and new investors, led by Corteva through their Corteva Catalyst platform,” said Arnon Heyman, Chief Executive Officer, IBI Ag. “This investment will help us to accelerate the development of our single domain antibody technology, providing farmers with sustainable and effective crop protection solutions. We believe our single domain antibody technology is a game changer for driving agricultural productivity while preserving the environment, and the investment announced today is a significant step towards delivering this innovation to farmers across the globe.”

“We see considerable potential for IBI Ag’s bioinsecticides to be a smart solution for farmers to tackle devastating insects while minimizing environmental impacts,” said Tom Greene, Senior Director at Corteva Inc. and Global Leader for Corteva Catalyst. “Our investment aligns with our continued drive to put cutting-edge innovation into the hands of farmers and reflects our strategic focus on accelerating development of next generation biological and naturally inspired solutions.”

About IBI Ag
IBI-Ag is a pioneer in the Agri-biotech industry, committed to developing innovative and sustainable solutions for crop protection. The company’s proprietary technology platform, the first of its kind, utilizes nano-bodies—a type of antibody—to create effective, selective, and safe biological insect control solutions. This breakthrough technology has the potential to protect the global food chain by helping farmers protect their crops with a lower ecological footprint and to transform the agricultural industry by offering an environmentally friendly and cost-effective alternative to chemical pesticides. IBI Ag was established by The Trendlines Group together with the founders Amir Ayali PhD and Rony Oren Benaroya PhD, and with the support of the Israel Innovation Authority.

Media Contacts:
IBI Ag: Arnon Heyman, CEO IBI Ag, e-mail: [email protected]

Photo – https://mma.prnewswire.com/media/2619674/IBI_Ag_team.jpg

SOURCE IBI Ag